Beatriz Grinsztejn, MD, PhD
Beatriz Grinsztejn, MD, PhD (Faculty Mentor; Brazil Site Director) is the director of the STD/AIDS Clinical Research Laboratory at IPEC/ FIOCRUZ and a faculty member of the graduate program in Clinical Research in Infectious Diseases. She is the principal investigator of the NIH ACTG and HPTN Clinical Trial Units at IPEC and was co-PI of the iPrEx antiretroviral prophylaxis study in Brazil. She is also co-PI of the Brazil-Agence Nationale du Control du SIDA (ANRS) collaboration for HIV Therapeutic Clinical Trials in Brazil. She is a member of the Optimization of Antiretroviral Therapy Committee of the ACTG and the Brazilian Adult Antiretroviral Therapy Guidelines Panel as well as a member of the HIV Research Advisory Board for the Brazilian Ministry of Health.
Optimization of antiretroviral therapy regimens for developing countries
Complications of antiretroviral therapy
Management of opportunistic infections
Grinsztejn B, Hosseinipour MC, Ribaudo HJ et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr;14(4):281-90.
Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM; ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014 Jun;14(6):459-67.
Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, Guimarães MR, Nunes EP, Lemos AS, Ribeiro SR, Campos DP, Vitoria MA, Veloso VG. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8(4):e59768.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.
Applications for the 2024-25 Fellowship class are now being accepted. The priority application deadline for the 2024-25 Fellowship class is February 16, 2024.